SCHEMBL7536306

SCHEMBL7536306

COc1ccc(S(=O)(=O)c2cc(F)c(F)c(F)c2F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.56
GAA P10253 1/20 0.49
RAPGEF4 Q8WZA2 1/20 0.47
HSD11B1 P28845 1/20 0.47
RXFP1 Q9HBX9 1/20 0.46
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CNR2 P34972 7/20 0.44
MMP2 P08253 2/20 0.43
MMP8 P22894 2/20 0.43
MMP12 P39900 2/20 0.43
MMP13 P45452 2/20 0.43
MMP14 P50281 2/20 0.43
MMP16 P51512 2/20 0.43
PKLR P30613 1/20 0.43
MMP9 P14780 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
CNR1 P21554 2/20 0.43
DRD4 P21917 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7533628 0.86 PKM (0.51) PKMGAARAPGEF4HSD11B1RXFP1
SCHEMBL7533096 0.81 PKM (0.68) PKMGAARAPGEF4HSD11B1HTT
SCHEMBL7534445 0.81 TSHR (0.62) PKMLMNAHTTSMN1; SMN2FFAR4
SCHEMBL7535728 0.81 TUBB1 (0.50) LMNAHTTSMN1; SMN2
SCHEMBL7540076 0.81 PKM (0.49) PKMGAAHSD11B1CNR2MMP2
SCHEMBL7537174 0.78 TUBB1 (0.52) SMN1; SMN2
SCHEMBL7533090 0.78 PKM (0.67) PKMGAARAPGEF4HSD11B1HTT
SCHEMBL7537143 0.77 ALDH1A1 (0.49) LMNAHTR6
SCHEMBL6675225 0.77 LMNA (0.56) GAALMNAHTTSMN1; SMN2TP53
SCHEMBL12434593 0.75 PKM (0.69) PKMGAARAPGEF4HSD11B1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed
US-6388131-B2 Benzenesulfonamide compounds, which encompasses the compound batabulin (2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene) TULARIK, INC. 2002-05-14 US disclosed
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US disclosed
US-6284923-B1 BENZENESULFONIMIDES FOR TREATMENT OF CANCER AND ANTICHOLESTEROL AGENTS TULARIK INC 2001-09-04 US disclosed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP disclosed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 PKM 3140/4885GAA 1364/4885RAPGEF4 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.